Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 15,160.6 | 11,396.6 | 6,416.7 | 6,022.1 | 4,934.3 | 4,527.4 | 4,158.1 | 4,158.1 |
| Revenue growth | 33.0% | 77.6% | 6.6% | 22.0% | 9.0% | 8.9% | 0.0% | 38.2% |
| Cost of goods sold | 4,700.8 | 3,816.5 | 969.0 | 979.3 | 670.8 | 585.8 | 551.7 | 551.7 |
| Gross profit | 10,459.8 | 7,580.1 | 5,447.7 | 5,042.8 | 4,263.5 | 3,941.6 | 3,606.4 | 3,606.4 |
| Gross margin | 69.0% | 66.5% | 84.9% | 83.7% | 86.4% | 87.1% | 86.7% | 86.7% |
| Selling, general and administrative | 3,530.9 | 3,015.2 | 1,842.5 | 1,782.0 | 1,651.3 | 1,948.0 | 1,675.7 | 1,675.7 |
| Research and development | 1,763.3 | 1,439.8 | 1,564.0 | 1,067.5 | 933.4 | 953.0 | 764.5 | |
| EBITA | 5,047.4 | 3,105.3 | 2,188.9 | 2,181.3 | 2,033.6 | 1,050.8 | 1,162.7 | 1,162.6 |
| EBITA margin | 33.3% | 27.2% | 34.1% | 36.2% | 41.2% | 23.2% | 28.0% | 28.0% |
| Amortization of intangibles | 1,768.4 | 1,173.4 | 498.7 | 243.8 | | | | |
| EBIT | 3,279.0 | 1,931.9 | 1,690.2 | 1,937.5 | 2,033.6 | 1,050.8 | 1,162.7 | 1,162.6 |
| EBIT margin | 21.6% | 17.0% | 26.3% | 32.2% | 41.2% | 23.2% | 28.0% | 28.0% |
| Pre-tax income | 1,893.4 | 486.1 | 1,385.8 | 3,336.2 | 1,693.6 | 1,007.8 | 1,117.1 | 645.8 |
| Income taxes | -2,357.6 | -126.1 | 46.1 | -56.1 | -277.9 | -203.1 | -236.9 | -236.9 |
| Tax rate | | | 3.3% | | | | | |
| Earnings from continuing ops | 4,235.5 | 879.6 | 1,371.6 | 3,160.1 | 2,174.1 | 866.0 | 900.4 | 882.7 |
| Earnings from discontinued ops | 18.0 | -276.1 | -34.1 | 122.7 | -754.5 | -60.3 | -17.7 | -17.7 |
| Net income | 4,253.5 | 603.5 | 1,337.5 | 3,282.8 | 1,419.6 | 805.7 | 882.7 | 865.0 |
| Net margin | 28.1% | 5.3% | 20.8% | 54.5% | 28.8% | 17.8% | 21.2% | 20.8% |
| |
| Diluted EPS | $4.64 | $1.13 | $2.31 | $5.34 | $3.68 | $1.46 | $1.51 | |
| Shares outstanding (diluted) | 912.0 | 776.2 | 593.1 | 591.3 | 590.3 | 593.5 | 595.4 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|